The "Dermatology Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global dermatology drugs market is expected to reach over $35 billion in 2020

Going forward, increase in the number of indications treated by topical drugs coupled with increase in acne and rosacea patients will drive the market for dermatology drugs.

The dermatology drugs market includes medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases.

Immune Modulators To Treat Eczema - Pharmaceutical companies are offering new drugs referred to as immune modulators for the treatment of skin diseases such as eczema. Eczema is a chronic skin condition caused by the lack of skin proteins that results in inflammation and irritation in the skin.

These drugs are used to externally treat the skin without changing the immune system of the body. In addition, unlike topical steroids, these new medications do not cause thinning of the skin and breaking of superficial blood vessels.

Tacrolimus (Protopic) and Pimecrolimus (Elidel) are major drugs available for the treatment of eczema.

Scope:

  • Markets Covered: Dermatology Drugs
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Johnson & Johnson
  • Allergan Plc.
  • Galderma S.A.
  • Novartis AG
  • GlaxosmithKline Plc.
  • Bayer AG
  • LEO Pharma A/S

For more information about this report visit https://www.researchandmarkets.com/research/dl2xg6/global?w=4